EYPT Q4 2023 Earnings — EyePoint Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

EYPTEyePoint Pharmaceuticals, Inc.

$1B

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$14M+33.2% YoY

Gross Profit

$13M92.9% margin

Operating Income

-$16M-116.6% margin

Net Income

-$14M-100.5% margin

EPS (Diluted)

$-0.33

QoQ Revenue Growth

-7.7%

Cash Flow

Operating Cash Flow

-$23M

Free Cash Flow

-$24M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$355M

Total Liabilities

$89M

Stockholders' Equity

$266M

Cash & Equivalents

$281M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$14M	$11M	+33.2%
Gross Profit	$13M	$7M	+82.9%
Operating Income	-$16M	-$44M	+62.6%
Net Income	-$14M	-$43M	+67.6%